FREQUENT PITFALLS IN ANTIHYPERTENSIVE THERAPY


Cite item

Full Text

Abstract

The most frequent pitfalls in antihypertensive therapy and approaches to overcome them are discussed

About the authors

V V Fomin

V V Panasyuk

References

  1. Kostis W.J., Thijs L., Richart T. et al. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension. 2010 Oct 25. [Epub ahead of print]
  2. Bramlage P., Böhm M., Volpe M. et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich). 2010; 12(9): 666-677
  3. Frohlich E.D. The necessity for recognition and treatment of patients with "mild" hypertension. J. Am. Coll. Cardiol. 1999; 34: 1369 - 1377
  4. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988 - 2000. J.A.M.A. 2003; 290: 199 - 206
  5. Macedo M.E., Lima M.J., Silva A.O. et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J. Hypertens. 2005; 23: 1661 - 1666
  6. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал. 2006; 4: 45-50
  7. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Качество профилактики и лечения сердечно-сосудистых заболеваний и их осложнений у больных сахарным диабетом 2 типа в амбулаторных условиях. Кардиоваскулярная терапия и профилактика 2008; 7(7): 9 - 14
  8. Чазов Е.И. Пути снижения смертности от сердечно-сосудистых заболеваний. Тер. арх. 2008; 80(8): 11-16
  9. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 3: 5-26
  10. McKay D.W., Campbell N.R., Parab L.S. et al. Clinical assessment of blood pressure. J. Hum Hypertens. 1990; 4: 639-645
  11. Isaacs A.J., Critchley J.A., Tai S.S. et al. Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only. Health Technol. Assess. 2007; 11(10): 1-165
  12. Farpour-Lambert N.J., Aggoun Y., Marchand L.M. et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J. Am. Coll. Cardiol. 2009; 54(25): 2396-2406
  13. Sugawara J., Otsuki T., Tanabe T. et al. Physical activity duration, intensity, and arterial stiffening in postmenopausal women. Am. J. Hypertens. 2006; 19(10): 1032-1036
  14. Gando Y., Yamamoto K., Murakami H. et al. Longer time spent in light physical activity is associated with reduced arterial stiffness in older adults. Hypertension. 2010; 56(3): 540-546
  15. Law M. Salt, blood pressure and cardiovascular diseases. J. Cardiovasc. Risk. 2000; 7: 5 - 8
  16. Destro M., Crikelair N., Yen J., Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc. Health Risk Manag. 2010; 6: 821-827
  17. Okin P.M., Hille D.A., Kjeldsen S.E. et al. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. Am. J. Hypertens. 2010; 23(7): 786-793
  18. Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545 - 1553
  19. Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895 - 906
  20. Zillich A.J., Garg J., Basu S. et al. Thiazide diuretics, potassium and the development of diabetes. A quantative review. Hypertension 2006; 48: 219 - 224
  21. Marazzi G., Volterrani M., Caminiti G. et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv. Ther. 2010; 27(9): 655-664
  22. Dragomir A., Côté R., Roy L. et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med. Care. 2010; 48(5): 418-425
  23. Bramley T.J., Gerbino P.P., Nightengale B.S., Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J. Manag. Care Pharm. 2006; 12(3): 239-245
  24. Fodor G.J., Kotrec M., Bacskai K. et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J. Hypertens. 2005; 23: 1261 - 1266
  25. Roth A., Kalter-Leibovici O., Kerbis Y. et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin. Cardiol. 2003; 26: 25 - 30
  26. Aranda P., Ruilope L.M., Calvo C. et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am. J. Hypertens. 2004; 17: 139 - 145
  27. Wannemacher A.J., Schepers G.P., Townsend K.A. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann. Pharmacother. 2002; 36: 986 - 991
  28. Salas M., In't Veld B.A., van der Linden P.D. et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin. Pharmacol. Ther. 2001; 70: 561 - 566
  29. Chapman R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 165: 1147 - 1152
  30. Schroeder K., Fahey T., Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst. Rev. 2004; 2: CD004804
  31. Neutel J.M., Saunders E., Bakris G.L. et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J. Clin. Hypertens. (Greenwich). 2005; 7(10): 578-586
  32. Chrysant S.G., Neutel J.M., Ferdinand K.C.; INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J. Natl. Med. Assoc. 2009; 101(4): 300-307
  33. Schmieder R.E., Schwertfeger M., Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc. Health Risk Manag. 2009; 5: 991-1000
  34. Franklin S.S., Neutel J.M. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. J. Clin. Hypertens. (Greenwich). 2010; 12(7): 487-494

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies